Stockscreener 앱 받기
9.2323
2.58%
0.2323
전일 마감가:
$9.00
열려 있는:
$8.99
하루 거래량:
360.10K
Relative Volume:
0.22
시가총액:
$912.37M
수익:
-
순이익/손실:
$-44.84M
주가수익비율:
-19.64
EPS:
-0.47
순현금흐름:
$-44.23M
1주 성능:
+4.32%
1개월 성능:
-9.57%
6개월 성능:
-31.61%
1년 성능:
-17.86%
1일 변동 폭
$8.91
$9.465
1주일 범위
$8.66
$9.64
52주 변동 폭
$6.66
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
명칭
Ars Pharmaceuticals Inc
전화
858-771-9307
주소
11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
Compare SPRY vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
9.23 | 889.64M | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.79 | 121.15B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
788.49 | 82.43B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
835.73 | 52.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.60 | 44.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
366.93 | 40.07B | 4.98B | 69.60M | 525.67M | 0.5198 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-04 | 재개 | Roth Capital | Buy |
| 2025-09-04 | 개시 | Roth Capital | Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-10 | 개시 | Oppenheimer | Outperform |
| 2024-08-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-13 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | 재확인 | Leerink Partners | Outperform |
| 2024-07-25 | 개시 | Raymond James | Outperform |
| 2024-03-05 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | 개시 | Wedbush | Outperform |
| 2023-01-03 | 개시 | William Blair | Outperform |
| 2022-12-13 | 개시 | SVB Leerink | Outperform |
모두보기
Ars Pharmaceuticals Inc 주식(SPRY)의 최신 뉴스
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences - Investing News Network
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Nasus Pharma Is Targeting a Validated Market With a Potentially Superior Intranasal Delivery Approach - GuruFocus
Levin Capital Strategies L.P. Increases Holdings in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
CenterBook Partners LP Invests $5.15 Million in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
How Recent Regulatory Twists Are Reframing The Story For ARS Pharmaceuticals (SPRY) - Yahoo Finance
How Ars Pharmaceuticals Inc. (SPRY) Affects Rotational Strategy Timing - Stock Traders Daily
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 7%Here's What Happened - MarketBeat
Practice Advances: A focus on neffy® (epinephrine nasal spray) - Patient Care Online
ARS Pharmaceuticals, Inc. $SPRY Shares Purchased by Aberdeen Group plc - MarketBeat
Got $300? 2 Biotech Stocks to Buy and Hold Forever - Yahoo Finance
ARS Pharmaceuticals outlines 2025 growth strategy with neffy commercialization and global expansion - MSN
What are ARS Pharmaceuticals Inc.’s earnings expectations2025 Risk Factors & Verified Momentum Stock Alerts - mfd.ru
Will ARS Pharmaceuticals Inc announce a stock splitTrade Volume Summary & Low Drawdown Investment Strategies - baoquankhu1.vn
Is ARS Pharmaceuticals Inc. stock vulnerable to regulatory risksSwing Trade & Weekly High Return Opportunities - mfd.ru
ARS Pharmaceuticals: Climbing Neffy Sales And Global Expansion Could Re-Rate The Stock - Seeking Alpha
Why hedge funds are buying ARS Pharmaceuticals Inc. stockJuly 2025 Reactions & High Win Rate Trade Alerts - mfd.ru
ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® at 2026 American Academy of Allergy, Asthma and Immunology Annual Scientific Meeting - Investing News Network
Needle-free epinephrine nasal spray may cut costs and boost patient preference - Stock Titan
Why ARS Pharmaceuticals Inc. stock remains on watchlists2025 Macro Impact & Weekly Return Optimization Alerts - mfd.ru
Market Moves: Is INHDs ROE strong enoughWeekly Trend Summary & Precise Trade Entry Recommendations - baoquankhu1.vn
(SPRY) and the Role of Price-Sensitive Allocations - Stock Traders Daily
SPRY SEC FilingsARS Pharms 10-K, 10-Q, 8-K Forms - Stock Titan
Will ARS Pharmaceuticals Inc. stock recover after earningsWeekly Loss Report & Capital Efficiency Focused Ideas - mfd.ru
ARS Pharmaceuticals, Inc. (SPRY) Stock Analysis: Eyeing a 171% Upside with Innovative Allergy Solutions - DirectorsTalk Interviews
How Investors May Respond To ARS Pharmaceuticals (SPRY) Expanding EURneffy Pediatric Use Across Europe - Yahoo Finance
Aquestive leaps, despite receiving CRL for Anaphylm NDA - The Pharma Letter
ARS Pharma Gets Positive CHMP Opinion For 1 Mg EURneffy Nasal Spray - Nasdaq
Needle-free allergy rescue for kids wins key EU support - Stock Titan
US FDA declines to approve Aquestive's oral drug for allergic reactions - Reuters
Targets Report: Will OceanPal Inc benefit from geopolitical trendsCPI Data & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Lisanti Capital Growth LLC Sells 208,886 Shares of ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
Weekly Recap: Will ARS Pharmaceuticals Inc announce a stock splitJuly 2025 Outlook & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
ARS Pharmaceuticals (NASDAQ:SPRY) Cut to Strong Sell at Zacks Research - MarketBeat
Repeat Offenders: Neffy, Anktiva Promotions Draw Another US FDA Untitled Letter After Crackdown - Citeline News & Insights
OPDP doubles up on ARS’s Neffy - Medical Marketing and Media
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Responsive Playbooks and the SPRY Inflection - Stock Traders Daily
Update Recap: Will ARS Pharmaceuticals Inc stock recover after earningsJuly 2025 Snapshot & Capital Efficient Trade Techniques - baoquankhu1.vn
Pullback Watch: Will ARS Pharmaceuticals Inc stock recover after earnings2025 Top Gainers & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
ARS Pharmaceuticals Reports Q3 2025 Financial Results - MSN
What ARS Pharmaceuticals (SPRY)'s neffyinSchools California Expansion Means For Shareholders - Sahm
Valuation Update: Is ARS Pharmaceuticals Inc a top pick in the sectorInsider Selling & Free High Return Stock Watch Alerts - baoquankhu1.vn
Aug Rallies: Can ARS Pharmaceuticals Inc generate free cash flowJuly 2025 Snapshot & AI Powered Market Entry Ideas - baoquankhu1.vn
Pullback Watch: Is ARS Pharmaceuticals Inc attractive at current valuationJuly 2025 Action & Weekly Consistent Profit Watchlists - baoquankhu1.vn
California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free ... - nrtoday.com
California K-12 Schools Now Eligible for neffyinSchools - GlobeNewswire
ARS Pharmaceuticals, Inc. (SPRY) Investor Outlook: Analyzing the 171% Upside Potential for This Biotech Stock - DirectorsTalk Interviews
Assessing ARS Pharmaceuticals (SPRY) Valuation After China Community Approval For Neffy Epinephrine Spray - simplywall.st
Understanding the Setup: (SPRY) and Scalable Risk - Stock Traders Daily
Is ARS Pharmaceuticals Inc a top pick in the sector2025 Fundamental Recap & Risk Controlled Daily Plans - baoquankhu1.vn
Ars Pharmaceuticals Inc (SPRY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Ars Pharmaceuticals Inc 주식 (SPRY) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Dorsey Brian | Chief Operating Officer |
Nov 13 '25 |
Sale |
8.71 |
21,828 |
190,050 |
10,789 |
| Chakma Justin | Chief Business Officer |
Nov 12 '25 |
Option Exercise |
0.84 |
30,000 |
25,200 |
166,380 |
| Chakma Justin | Chief Business Officer |
Nov 12 '25 |
Sale |
8.87 |
166,380 |
1,476,147 |
0 |
0.88%
0.83%
자본화:
|
볼륨(24시간):